VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson
CARY, N.C., September 25, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Servier as a limited specialty pharmacy provider for VORANIGO (vorasidenib) for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma oroligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate […]
ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson
CARY, N.C., September 10, 2024 –Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Sentynl Therapeutics, Inc., as the exclusive specialty pharmacy for ZOKINVY® (lonafarnib) in the United States. ZOKINVY is approved by the U.S. Food and Drug Administration (FDA) in patients 12 months of age and older […]
RYTELO (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson
CARY, N.C., September 9, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Geron Corporation as a limited specialty pharmacy provider for RYTELO™ (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell […]
CAMCEVI® (leuprolide) 42mg injection emulsion, FDA Approved for Treatment of Advanced Prostate Cancer, Available Exclusively at Biologics by McKesson
CARY, N.C., June 19, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Accord BioPharma, Inc. as an exclusive specialty pharmacy provider for CAMCEVI (leuprolide) 42mg injection emulsion, for subcutaneous use. Approved by the U.S. Food and Drug Administration (FDA) on May 25, 2021, CAMCEVI is a […]
OJEMDA (tovorafenib), FDA Approved for Pediatric Low-Grade Glioma, Available at Biologics by McKesson
CARY, N.C., April 23, 2024 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Day One Biopharmaceuticals, as a limited network specialty pharmacy for OJEMDA™ (tovorafenib) for the treatment of pediatric low-grade glioma (pLGG). OJEMDA, granted Rare Pediatric Disease Designation and approved by the U.S. Food and Drug […]
FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson
CARY, N.C., Dec. 20, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Novartis as a specialty pharmacy provider for FABHALTA® (iptacopan). FABHALTA, approved by the U.S. Food and Drug Administration (FDA) on Dec. 5, 2023, is the first oral monotherapy for the treatment of adults […]
OGSIVEO (nirogacestat) FDA Approved for Desmoid Tumors, Available at Biologics by McKesson
CARY, N.C., Dec.5, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by SpringWorks Therapeutics as a limited distribution specialty pharmacy for OGSIVEO™ (nirogacestat), which is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment. OGSIVEO, which was approved on Nov. 27, 2023, […]
TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson
CARY, N.C., Dec.1, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by AstraZeneca as a specialty pharmacy provider for TRUQAP™ (capivasertib). TRUQAP, which was approved by the U.S. Food and Drug Administration (FDA) on Nov. 17, 2023, is an orally administered drug, in combination with fulvestrant, for the […]
FRUZAQLA (fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson
CARY, N.C., Nov. 15, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Takeda as a specialty pharmacy provider for FRUZAQLATM (fruquintinib). FRUZAQLA, approved by the U.S. Food and Drug Administration (FDA) on Nov. 8, 2023, is an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) […]
OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia, Available at Biologics by McKesson
CARY, N.C., Sept. 20, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by GSK as a specialty pharmacy provider for OJJAARA™ (momelotinib). OJJAARA, approved by the U.S. Food and Drug Administration (FDA) on September 15, 2023, is an orally administered drug for the treatment of myelofibrosis (MF) in adults […]